Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748998 | PMC |
| http://dx.doi.org/10.2106/JBJS.L.01370 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy.
Nucl Med Biol
December 2024
Life Sciences Division, TRIUMF, BC V6T 2A3 Vancouver, British Columbia, Canada; Department of Chemistry, University of British Columbia, V6T 1Z1 Vancouver, British Columbia, Canada.
Targeted Alpha Therapy has shown great promise in cancer treatment, sparking significant interest over recent decades. However, its broad adoption has been impeded by the scarcity of alpha-emitters and the complexities related to their use. The availability of these radionuclides is often constrained by the intricate production processes and purification, as well as regulatory and logistical challenges.
View Article and Find Full Text PDFOver the past two decades, extensive research has focused on both the fundamental and applied aspects of nanomedicine, driven by the compelling advantages that nanoparticles offer over their bulk counterparts. Despite this intensive research effort, fewer than 100 nanomedicines have been approved by the U.S.
View Article and Find Full Text PDFClinical genetic services in the Emilia-Romagna region, Italy: current activity and open issues: a mixed-method study.
J Community Genet
January 2025
Medical Genetics Unit, University Hospital of Parma, Parma, Italy.
In 2002, in the Emilia-Romagna region of Italy, a comprehensive strategic plan was developed with the aim of improving the integration and efficiency of the genetic services. Two decades later, this report aims to explore the current functioning of the regional network, with special focus on clinical genetics in the evolving scenarios. To this aim, we analyzed the activity data of the medical genetics services in the region, to identify and possibly improve currently open issues.
View Article and Find Full Text PDFStrategic Optimization of the Middle Domain IIIA in RBP-Albumin IIIA-IB Fusion Protein to Enhance Productivity and Thermostability.
Int J Mol Sci
December 2024
Department of Biomedical Sciences, College of Medicine, Korea University, Seoul 02841, Republic of Korea.
The protein therapeutics market, including antibody and fusion proteins, has experienced steady growth over the past decade, underscoring the importance of optimizing amino acid sequences. In our previous study, we developed a fusion protein, R31, which combines retinol-binding protein (RBP) with albumin domains IIIA and IB, linked by a sequence (AAAA), and includes an additional disulfide bond (N227C-V254C) in IIIA. This fusion protein effectively inhibited hepatic stellate cell activation.
View Article and Find Full Text PDFStereoselective Conversions of Carbohydrate Anomeric Hydroxyl Group in Basic and Neutral Conditions.
Molecules
December 2024
Department of Chemistry, University of Massachusetts Boston, Boston, MA 02125, USA.
The rapidly growing glycoscience has boosted the research on the synthesis of glycans and their conjugates, which are centered on the stereoselective formation of glycosidic bonds. Compared to the mainstream acid-promoted glycosylation method that undergoes the S1 type mechanism, the basic/neutral conditions give better stereo control via the S2 mechanism. Anomeric hydroxyl group transformation, whether to form glycosidic bonds directly or to install a leaving group for later glycosylation, is key to carbohydrate synthesis, and the strategies in the stereo control of these reactions under basic/neutral conditions are summarized in this review.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!